Ingenium Therapeutics
PrivateLast Round
Series A
Nov 21, 2023
Total Funding Raised
$8.91M
Company Overview
Ingenium Therapeutics is a biotechnology company that develops next-generation cancer therapies based on innate immunity and NK cells for treatments of leukemia and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ingenium Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Ingenium Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 21, 2023 | ||||
| Pre Seed | Apr 1, 2022 |
Ingenium Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K-Ground Ventures | Series A |
| Daewoodang Healthcare | Series A |
| Capstone Partners Korea | Series A |
| Laplace Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 21, 2023
$4.05M round led by Capstone Partners Korea.
- Apr 1, 2022
$4.86M raised in Pre Seed round.
Ingenium Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ingenium Therapeutics's valuation, stock price, and market status.
